Brief: Applied Molecular To Report Top-Line Phase 2 Results From Market Combination Trial Of Oral AMT-101 In Patients With Moderate-To-Severe Ulcerative Colitis
05/07/2022 21:09
July 5 (Reuters) - Applied Molecular Transport Inc.
AMTI.O :
* APPLIED MOLECULAR TRANSPORT TO REPORT TOP-LINE PHASE 2
RESULTS
FROM MARKET COMBINATION TRIAL OF ORAL AMT-101 IN PATIENTS WITH
MODERATE-TO-SEVERE ULCERATIVE COLITIS
Source text for Eikon: ID:nGNX78Xn2s
Further company coverage: AMTI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Applied Molecular Transport.
See all newsApplied Molecular Transport Inc. expected to post a loss of 50 cents a share - Earnings Preview
Brief: Applied Molecular Transport Inc. - On Oct 23 Got Written Notice Nasdaq Had Granted Co's Request For Continued Listing On Nasdaq
U.S. STOCKS ON THE MOVE-Boston Scientific, Rockwell Medical, Visa
U.S. STOCKS ON THE MOVE-Fox Corp, Cisco Systems, Darden Restaurants
Applied Molecular rises on merger deal with Cyclo Therapeutics